Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 5/20 | 0.53 |
| ▸ | ABL1 | P00519 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | GLA | P06280 | 2/20 | 0.45 |
| ▸ | CASP1 | P29466 | 1/20 | 0.45 |
| ▸ | CASP7 | P55210 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | CFTR | P13569 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | CLCN2 | P51788 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL313281 | 0.84 | ALDH1A1 (0.54) | KDM4EPOLBALDH1A1MAPTHPGD | |
| SCHEMBL312482 | 0.84 | ALDH1A1 (0.46) | GAAKDM4EHSD17B10ALDH1A1MAPT | |
| SCHEMBL1552911 | 0.84 | KDM4E (0.55) | GAAABL1KDM4EPOLBHSD17B10 | |
| SCHEMBL7555029 | 0.82 | ABL1 (0.54) | GAAABL1KDM4EPOLBHSD17B10 | |
| SCHEMBL857226 | 0.81 | KDM4E (0.65) | GAAABL1KDM4EPOLBHSD17B10 | |
| SCHEMBL2212660 | 0.81 | KDM4E (0.51) | GAAABL1KDM4EPOLBHSD17B10 | |
| SCHEMBL13959837 | 0.81 | GAA (0.46) | GAAABL1KDM4EHSD17B10ALDH1A1 | |
| SCHEMBL22219653 | 0.81 | GAA (0.50) | GAAABL1KDM4EHSD17B10ALDH1A1 | |
| SCHEMBL27972201 | 0.80 | HMGCR (0.46) | KDM4EALDH1A1KMT2AMEN1MAPK1 | |
| SCHEMBL24558234 | 0.79 | ABL1 (0.51) | GAAABL1KDM4EPOLBHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3126354-B1 | HALOGENATED QUINAZOLIN-THF-AMINES AS PDE1 INHIBITORS | H LUNDBECK AS (DK) | 2020-01-22 | — | — | EP | disclosed |
| US-20190144434-A1 | HALOGENATED QUINAZOLIN-THF-AMINES AS PDE1 INHIBITORS | H. LUNDBECK A/S (DK) | 2019-05-16 | — | — | US | disclosed |
| US-10005764-B2 | Halogenated quinazolin-THF-amines as PDE1 inhibitors | H. LUNDBECK A/S (DK) | 2018-06-26 | — | — | US | disclosed |
| EP-3126354-A1 | HALOGENATED QUINAZOLIN-THF-AMINES AS PDE1 INHIBITORS | H. Lundbeck A/S (DK) | 2017-02-08 | — | — | EP | disclosed |
| US-20170022186-A1 | Halogenated Quinazolin-THF-Amines as PDE1 Inhibitors | H. LUNDBECK A/S (DK) | 2017-01-26 | — | — | US | disclosed |
| US-9353100-B2 | Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections | IDENIX PHARMACEUTICALS LLC (US) | 2016-05-31 | — | — | US | disclosed |
| EP-2461811-B1 | MACROCYCLIC SERINE PROTEASE INHIBITORS USEFUL AGAINST VIRAL INFECTIONS, PARTICULARLY HCV | IDENIX PHARMACEUTICALS LLC (US) | 2016-04-20 | — | — | EP | disclosed |
| US-9284307-B2 | Macrocyclic serine protease inhibitors | IDENIX PHARMACEUTICALS LLC (US) | 2016-03-15 | — | — | US | disclosed |
| WO-2015150254-A1 | HALOGENATED QUINAZOLIN-THF-AMINES AS PDE1 INHIBITORS | H. LUNDBECK A/S (DK) | 2015-10-08 | — | — | WO | disclosed |
| US-8993595-B2 | Macrocyclic serine protease inhibitors | IDENIX PHARMACEUTICALS, INC. (US) | 2015-03-31 | — | — | US | disclosed |
| US-20110129443-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | IDENIX PHARMACEUTICALS, INC. (US) | 2011-06-02 | — | — | US | disclosed |
| WO-2011017389-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS USEFUL AGAINST VIRAL INFECTIONS, PARTICULARLY HCV | IDENIX PHARMACEUTICALS, INC. (US) | 2011-02-10 | — | — | WO | disclosed |
| EP-2250174-A2 | MACROCYCLIC SERINE PROTEASE INHIBITORS | IDENIX Pharmaceuticals, Inc. (US) | 2010-11-17 | — | — | EP | disclosed |
| WO-2010118078-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | IDENIX PHARMACEUTICALS, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
| US-20100260710-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | IDENIX PHARMACEUTICALS, INC. (US) | 2010-10-14 | — | — | US | disclosed |
| US-20100016578-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | IDENIX PHARMACEUTICALS, INC. (US) | 2010-01-21 | — | — | US | disclosed |
| WO-2009099596-A2 | MACROCYCLIC SERINE PROTEASE INHIBITORS | IDENIX PHARAMACEUTICALS, INC. (US) | 2009-08-13 | — | — | WO | disclosed |
| US-20090202480-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | IDENIX PHARMACEUTICALS, INC. (US) | 2009-08-13 | — | — | US | disclosed |
| CN-1091100-C | N-arylsulfilimine compounds and their use as catalysts for the preparation of N-arylarylsulfonamide compounds | DOW AGROSCIENCES LLC (US) | 2002-09-18 | — | — | CN | disclosed |
| CN-1216040-A | N-arylsulfilimine compounds and their use as catalysts in preparation of N-arylarylsulfonamide compounds | DOW AGROSCIENCES LLC (US) | 1999-05-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190144434-A1 | HALOGENATED QUINAZOLIN-THF-AMINES AS PDE1 INHIBITORS | PDE12, PDE3A, PDE7B | GAA 529/4885ABL1 215/4885KDM4E 1012/4885 |
| US-10005764-B2 | Halogenated quinazolin-THF-amines as PDE1 inhibitors | PDE12, PDE3A, PDE7B | GAA 529/4885ABL1 215/4885KDM4E 1012/4885 |
| US-20090202480-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | SERPINB1, SPINT2, PRSS1 | GAA 368/4885ABL1 2006/4885KDM4E 3667/4885 |
| US-20170022186-A1 | Halogenated Quinazolin-THF-Amines as PDE1 Inhibitors | PDE12, PDE3A, PDE7B | GAA 529/4885ABL1 215/4885KDM4E 1012/4885 |
| US-20100016578-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | SERPINB1, SPINT2, PRSS1 | GAA 368/4885ABL1 2006/4885KDM4E 3667/4885 |
| US-20110129443-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | SERPINB1, SPINT2, PRSS1 | GAA 388/4885ABL1 1841/4885KDM4E 3609/4885 |
| US-20100260710-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | SERPINB1, SPINT2, PRSS1 | GAA 388/4885ABL1 1841/4885KDM4E 3609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.